Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 18/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | CCKBR | P32239 | 1/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.60 |
| ▸ | ECE1 | P42892 | 1/20 | 0.59 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15086005 | 0.94 | GLP1R (0.67) | GLP1RRXFP1CCKBRNR3C1ECE1 | |
| SCHEMBL10083215 | 0.93 | GLP1R (0.70) | GLP1RCCKBRNR3C1ECE1MUS81 | |
| SCHEMBL2752275 | 0.93 | GLP1R (0.70) | GLP1RCCKBRNR3C1ECE1MUS81 | |
| SCHEMBL6123960 | 0.92 | GLP1R (0.69) | GLP1RCCKBRNR3C1ECE1MUS81 | |
| SCHEMBL15024692 | 0.88 | GLP1R (0.67) | GLP1RCCKBRNR3C1ECE1MUS81 | |
| SCHEMBL2759455 | 0.88 | NR3C1 (0.70) | GLP1RCCKBRNR3C1ECE1MUS81 | |
| SCHEMBL2742706 | 0.88 | NR3C1 (0.70) | GLP1RCCKBRNR3C1ECE1MUS81 | |
| SCHEMBL12873154 | 0.88 | GLP1R (0.67) | GLP1RCCKBRNR3C1ECE1MUS81 | |
| SCHEMBL5959058 | 0.87 | GLP1R (0.68) | GLP1RCCKBRNR3C1ECE1MUS81 | |
| SCHEMBL12393243 | 0.87 | GLP1R (0.70) | GLP1RNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846712-B2 | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20130065894-A1 | 6-(4-HYDROXY-PHENYL)-3-STYRYL-1H-PYRAZOLO[3,4-b]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065894-A1 | 6-(4-HYDROXY-PHENYL)-3-STYRYL-1H-PYRAZOLO[3,4-b]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | MAP3K1, MAP4K2, MAP3K6 | GLP1R 261/4885RXFP1 1780/4885CCKBR 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.